dermatology

News

Rare disease drug from LEO's Timber felled by failed study

Just a few months after buying Timber Pharma, LEO Pharma has revealed that the main drug it acquired as part of the deal has failed a phase 3 trial.

News

Galderma's chief executive Flemming Ørnskov

Galderma gets FDA nod for prurigo nodularis therapy

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales.

News

physician holds hand of a person with chronic hand eczema

LEO closes on first approval for chronic hand eczema drug

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

News

After FDA delay, Arcutis gets Zoryve OK in atopic dermatitis

After a couple of days filled with investor nervousness, Arcutis Biotherapeutics has claimed FDA approval of Zoryve for the new indication of atopic dermatitis (AD), a common form of eczema

News

Survey reveals heavy burden of chronic hand eczema

People with chronic hand eczema (CHE) have reported the serious impact the condition can have on their daily lives in a UK survey.

News

Close-up view of an actinic keratosis lesion

FDA OKs wider use of Almirall’s actinic keratosis drug

With actinic keratosis (AK) diagnoses on the rise, there is some good news for patients, with the FDA approval of expanded use of Almirall’s topical therapy Klisyri.

Rare disease drug from LEO's Timber felled by failed study

Galderma gets FDA nod for prurigo nodularis therapy

LEO closes on first approval for chronic hand eczema drug

After FDA delay, Arcutis gets Zoryve OK in atopic dermatitis

Survey reveals heavy burden of chronic hand eczema

FDA OKs wider use of Almirall’s actinic keratosis drug

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

dermatology

Editor's Picks